National Institute on Drug Abuse; Notice of Closed Meeting, 33690 [2020-11804]

Download as PDF 33690 Federal Register / Vol. 85, No. 106 / Tuesday, June 2, 2020 / Notices ESTIMATED ANNUALIZED BURDEN TABLE—Continued Number of respondents Type of respondent Average burden per response (in hours) Total burden hours TPP Grantees (training) ................................................................................... TPP Grantees (dissemination) ........................................................................ TPP Grantees Stakeholder Engagement ........................................................ Tier 1 and Tier 2 Phase II grantees (Reach and Demographics) ................... Tier 1 and Tier 2 Phase II grantees (Dosage) ................................................ Tier 1 and Tier 2 Phase II grantees (Fidelity and Quality) .............................. Tier 2 Innovation Network Item ....................................................................... Tier 1 Grantees (Supportive Services) ............................................................ 90 90 90 64 64 64 14 54 2 2 2 2 2 2 2 2 15/60 30/60 15/60 3 2 2 15/60 15/60 45 90 45 384 256 256 7 27 Total .......................................................................................................... 90 2 ........................ 1155 Sherrette A. Funn, Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer. [FR Doc. 2020–11862 Filed 6–1–20; 8:45 am] BILLING CODE 4150–34–P National Institutes of Health [FR Doc. 2020–11804 Filed 6–1–20; 8:45 am] National Institute on Drug Abuse; Notice of Closed Meeting BILLING CODE 4140–01–P Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic. Date: July 15–16, 2020. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neurosciences Center Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, Room 4235, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892–9550, (301) 827–5819, gm145a@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist VerDate Sep<11>2014 20:46 Jun 01, 2020 Jkt 250001 Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: May 27, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES khammond on DSKJM1Z7X2PROD with NOTICES Number responses per respondent DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Biomedical Computing and Health Informatics Study Section. Date: June 25–26, 2020. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Chittari V. Shivakumar, Ph.D., Scientific Review Officer, National PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 408–9098, chittari.shivakumar@ nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business Applications: Drug Discovery and Development. Date: June 29–30, 2020. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sergei Ruvinov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, (301) 435– 1180, ruvinser@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Motor Function, Speech and Rehabilitation Study Section. Date: June 29–30, 2020. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Biao Tian, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, MSC 7848, Bethesda, MD 20892, (301) 402–4411, tianbi@csr.nih.gov. Name of Committee: Oncology 1—Basic Translational Integrated Review Group; Cancer Molecular Pathobiology Study Section. Date: June 29–30, 2020. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I,I 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Manzoor Zarger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892, (301) 435– 2477, zargerma@csr.nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review E:\FR\FM\02JNN1.SGM 02JNN1

Agencies

[Federal Register Volume 85, Number 106 (Tuesday, June 2, 2020)]
[Notices]
[Page 33690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11804]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: America's Startups and Small 
Businesses Build Technologies to Stop the Opioid Epidemic.
    Date: July 15-16, 2020.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, Room 4235, MSC 9550, 6001 Executive Boulevard, 
Bethesda, MD 20892-9550, (301) 827-5819, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)


    Dated: May 27, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-11804 Filed 6-1-20; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.